Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy.

Literature DB >> 22896596

Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy.

Teng Moua, Eric J Olson, Hope C St Jean, Jay H Ryu.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2012 PMID： 22896596 DOI： 10.1164/ajrccm.186.4.389

Source DB: PubMed Journal: Am J Respir Crit Care Med ISSN： 1073-449X Impact factor: 21.405

Keyword Cloud
Cited

× No keyword cloud information.

9 in total

1. Rapamycin induces mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) expression through activation of protein kinase B and mitogen-activated protein kinase kinase pathways.

Authors: Ruchi Rastogi; Zhongliang Jiang; Nisar Ahmad; Rita Rosati; Yusen Liu; Laurent Beuret; Robert Monks; Jean Charron; Morris J Birnbaum; Lobelia Samavati
Journal: J Biol Chem Date: 2013-10-14 Impact factor: 5.157

2. Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.

Authors: Angelo M Taveira-DaSilva; Amanda M Jones; Patricia Julien-Williams; Thomas Shawker; Connie G Glasgow; Mario Stylianou; Joel Moss
Journal: Chest Date: 2015-10 Impact factor: 9.410

3. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.

Authors: Angelo M Taveira-DaSilva; Amanda M Jones; Patricia Julien-Williams; Mario Stylianou; Joel Moss
Journal: Chest Date: 2017-05-19 Impact factor: 9.410

Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy.

1. Rapamycin induces mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) expression through activation of protein kinase B and mitogen-activated protein kinase kinase pathways.

2. Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.

3. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.

4. Adolescent form of sporadic lymphangioleiomyomatosis (S-LAM).

Review 5. Pulmonary manifestations in tuberous sclerosis complex.

6. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.

7. Recovery of chylous pulmonary congestion in tuberous sclerosis complex-associated lymphangioleiomyomatosis.

8. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.

9. EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.